Pagliaro, M.; Pagliaro, M.; Meneguzzo, F.; Meneguzzo, F. Hydroxychloroquine for the Treatment of Coronavirus Disease 2019: Evidence, Possible Mode of Action and Industrial Supply. Medicine Research 2020, 4, 200014, doi:10.21127/yaoyimr20200014.
Pagliaro, M.; Pagliaro, M.; Meneguzzo, F.; Meneguzzo, F. Hydroxychloroquine for the Treatment of Coronavirus Disease 2019: Evidence, Possible Mode of Action and Industrial Supply. Medicine Research 2020, 4, 200014, doi:10.21127/yaoyimr20200014.
Pagliaro, M.; Pagliaro, M.; Meneguzzo, F.; Meneguzzo, F. Hydroxychloroquine for the Treatment of Coronavirus Disease 2019: Evidence, Possible Mode of Action and Industrial Supply. Medicine Research 2020, 4, 200014, doi:10.21127/yaoyimr20200014.
Pagliaro, M.; Pagliaro, M.; Meneguzzo, F.; Meneguzzo, F. Hydroxychloroquine for the Treatment of Coronavirus Disease 2019: Evidence, Possible Mode of Action and Industrial Supply. Medicine Research 2020, 4, 200014, doi:10.21127/yaoyimr20200014.
Abstract
Hydroxychloroquine, a known antiviral metabolite of chloroquine, is increasingly used along with antibiotic azithromycin for the treatment of COVID-19 infection. In about one month India, the world’s largest manufacturer, delivered hydroxychloroquine for treating COVID-19 to over 50 countries. The therapy is being used across the world both for patients staying at home at the early phase of symptoms, as well as for patients hospitalized. We summarize achievements as of late April 2020, review possible modes of action and suggest avenues for the quick scale-up of production of hydroxychloroquine.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
